# FDA Panel Backs Truqap In Prostate Cancer.

*biotech · news · 2026-05-01 · Benzinga*

## Key points

- The FDA panel endorsed Truqap with abiraterone for PTEN-deficient mHSPC based on CAPItello-281 data.
- Truqap combination improved median radiographic progression-free survival to 33.2 months versus 25.7 months.
- Grade 3 or higher adverse events were more frequent in the Truqap arm but manageable.
- The FDA panel rejected camizestrant for HR-positive, HER2-negative breast cancer despite strong progression risk reduction.
- A later pre-planned analysis showed camizestrant provided a significant PFS2 benefit of 25.7 months.

**Companies:** AstraZeneca
**Countries:** United States

[Read the full story on Benzinga](https://www.benzinga.com/news/fda/26/05/52209523/astrazeneca-prostate-drug-wins-fda-panel-backing-as-breast-cancer-candidate-falters)

---

Canonical: https://newsio.io/n/5a028ab2-3b30-4f11-a311-e9343505374c/fda-panel-backs-truqap-in-prostate-cancer-odac-voted-3-6-against-astrazenecas-ca
Summarized by Newsio from Benzinga. https://newsio.io/how-it-works